N onalcoholic fatty liver disease (NAFLD) can progress from simple steatosis to nonalcoholic steatohepatitis and liver cirrhosis. NAFLD is often associated with metabolic syndrome elements such as obesity, hyperlipidemia, type 2 diabetes, and insulin resistance (1-3). The key role of insulin resistance in the course of NAFLD has been shown in several studies. Eliminating of insulin resistance can prevent the development of NAFLD (4-6).
Metformin is an oral antidiabetics that shows the lowering effect on blood glucose by a reduction in hepatic glucose production and by an increase in insulin-dependent glucose uptake in skeletal muscle. It reduces the fatty acid oxidation in muscles and liver, and also shows positive effects on plasma lipid profile by reducing low-density lipoprotein cholesterol and very low density lipoprotein cholesterol (7). Omentin released from the visceral adipose tissue increases the activity of insulin in glucose metabolism and transport of glucose stimulated by insulin in subcutaneous adipocytes as well as in omental adipocytes. It was reported that serum omentin levels have decreased in obesity and insulin resistance (8, 9). Omentin gene expression has been decreased in obesity; decreased plasma omentin levels have been associated with increased obesity and insulin resistance (10).
Although omentin levels were found to be lower in patients with steatohepatitis, no research study has been performed to evaluate the effect of metformin therapy on omentin levels. Therefore, the purpose of this study is to examine the omentin levels in type 2 diabetic patients with hepatic steatosis and to compare the effects of diet and the diet plus metformin treatment on omentin levels.
MAterIAls And Methods
This prospective cohort study was conducted at the Harran University School of Medicine, Sanliurfa, Turkey. Prior to subject recruitment, the study protocol was reviewed and approved by the local ethics committee, in accordance with the ethical principles for human investigations, as outlined by the Second Declaration of Helsinki, and written informed consent was obtained from all the patients. Consecutively 88 patients who had hepatic steatosis with type-2 DM were recruited for the study.
The exclusion criteria were as follows: pregnancy; patients should be started insulin or insulin secretagogue; patients with contraindication to initiation of metformin; diabetic ketoacidosis; acute or chronic metabolic acidosis; renal failure; congestive heart failure; chronic liver disease; recent myocardial infarction; acute or chronic alcoholism; hypoxemia; and those against hypersensitivity to any component of the medication.
88 consecutive T2D patients with hepatic steatosis were recruited. Per protocol, 28 patients were excluded from the study. The remaining 60 patients were randomized into two groups. Group 1 (n=30) was assigned to diet alone; group 2 (n=30) received diet + metformin for 3 months. 5 patients in group 1 and 1 patient in group 2 were lost to follow-up, accordingly, 25 patients in group 1 and 29 patients in group 2 were evaluated ( Figure 1 ).
The diagnosis of diabetes mellitus was based on the American Diabetes Association 2012 criteria and on a previous history of diabetes (anti-diabetic medications usage), and NAFLD was diagnosed according to hepatobiliary ultrasound findings. Ultrasound findings for NAFLD were a diffuse hyperechoic echotexture (bright liver), increased liver echotexture compared with the kidneys, vascular blurring, and deep attenuation (11, 12) .
Height and weight were measured according to standard protocols. Body mass index (BMI) was calculated as the person's weight in kilograms divided by his or her height in meters squared (kg/m 2 ). Body compositions were assessed with bioelectrical impedance analysis (BF 510, Omron Healthcare Co. Ltd., Kyoto, Japan). HOMA-IR was used to evaluate insulin sensitivity of patients. HOMA-IR was calculated by the formula: [fasting serum glucose (mg / dl) x fasting serum insulin (μıU / ml)] / 405. Other biochemical analyses were determined using commercially available assay kits (Abbott, Abbott Park, USA) with an auto-analyzer (Abbott, Abbott Park, USA).
At the beginning and end of the study, 7 ml of venous blood samples were taken from each patient to analyze omentin levels and were placed in biochemistry tubes. Venous blood samples were separated serums after centrifugation at 3500 rpm for 10 minutes and serum samples were immediately stored at -80 °C until working time by putting into a special box. Serum omentin-1 levels were determined using an omentin-1 Enzyme Linked Immuno Sorbent Assay (ELISA; BioVendor Laboratorni medicina, Brno, Czech Republic). The results were formed in accordance with quality control serums and controls and were calculated according to the calibration curve. Omentin levels are referred in ng / mL.
All statistical analyses were performed using SPSS 20.0 for Windows (SPSS, Chicago, IL, USA). KolmogorovSmirnov tests were used to test the normality of the data distribution. The data were expressed as the mean and standard deviation. The chi-square test was used to compare the categorical variables between groups. Independent Sample T test and Mann-Whitney U tests were used for normally and nonnormally distributed continuous data, respectively. Paired t-test and Wilcoxon signed-rank tests were used to analyze changes in each group. A two-sided p value < 0.05 was considered to be statistically significant. The demographic, anthropometric and laboratory parameters of both groups before treatment are shown in Table 1 . There was no statistically significant difference in terms of clinical and demographic data between the two groups. When considered the effect of treatment; there was a statistically significant difference in the values of body weight, BMI, waist and hip circumference, body fat percentage (%), HOMA-IR, HbA1c, glucose and omentin in group 1, and in the values of body weight, BMI, waist and hip circumference, body fat percentage (%), HOMA-IR, glucose, triglycerides, and omentin in group 2 (Table 2, 3).
Omentin levels were significantly decreased with the treatment in both groups (5.37 ± 1.31 ng/ml to 4.00 ± 1.46 ng/ml in group 1; 6.96 ± 2.10 ng/ml to 3.92 ± 0.89 ng/ml in group 2, p = 0.001 respectively) (Figure 2) . When compared the percentage of change between two groups, it was found that the omentin value was more decreased in group 2 (p = 0.032) (Figure 3) . To the best of our knowledge, this is the first showing the effect of metformin therapy on body weight and the omentin level in type 2 diabetes mellitus patients with NAFLD.
Insulin resistance is the major factors behind the alterations of uptake, synthesis, degradation, and secretion of free fatty acids in the liver which leads to accumulation of lipids that cause the NAFLD (13) . It has been shown that insulin resistance and fatty acid metabolism improved after significant weight loss (14, 15) . Additionally, there are many studies reporting that losing weight provide improvement of histology (16, 17) . Metformin is a first-line oral anti-hyperglycemic that improves insulin sensitivity in the liver and skeletal muscle (18). Metformin is not caused Variables were expressed as mean ± standard deviations. NS: Not significant; BMI: Body Mass Index; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; HbA1c: glycated haemoglobin; HOMA-IR: homeostasis model assessment of insulin resistance weight gain and, in fact, it has been shown to induce modest weight loss (19) (20) (21) (22) . We detected that metformin did not provide additional impact to the weight-loss effect of diet therapy in diabetic patients with NAFLD.
It has been shown that omentin levels are increased in obese subjects after weight loss (23) . Reduced omentin levels in patients with diabetes are also observed (24, 25) . Interestingly, Yılmaz et al. showed that serum omentin levels are raised in patients with NAFLD, omentin levels are positively associated with hepatocyte ballooning -indicator of hepatocyte degeneration-independent of insulin resistance and some features of the metabolic syndrome (26) . They also hypothesized that omentin might play a role in the development and progression of NAFLD. We detected that omentin levels are increased with loss of weight contrary to literature. NAFLD may be a confounder; so that, we suggest additional studies to identify reasons for this paradoxical increase as proposition of Yılmaz et al. (26) .
Studies concluded that metformin did not improve findings of liver histology included steatosis, lobular inflammation, hepatocellular ballooning and fibrosis in NAFLD (27) . Other studies demonstrated that metformin treatment decreased omentin levels in diabetes and polycystic ovary syndrome (28, 29) . However, Esteghamati et al. found that both insulin sensitizers -metformin and pioglitazone-are decresed serum omentin concentrations in diabetic patients (30) . In another study, Kim et al. found that metformin enhanced insulin sensitivity via independent mechanisms from phosphatidylinositol 3-kinase activity (31) . Estagmati et al. hypothesized that after restored of insulin sensitivity, Akt signaling and its upstream mediators such as omentin might be suppressed.
Therefore, insulin sensitizers paradoxically inhibit the omentin by this negative feedback mechanism (32). Our similar results may be explained by this way.
When all of these data taken into account, metformin seem to not to provide additional benefits compared to weight loss. At present guidelines, metformin is not recommended as a primary treatment especially from the standpoint of nonalcoholic steatohepatitis (33) . We can also say that it can be used in diabetic patients with NAFLD for other indications as recommended previously (34) . Furthermore, the interactions of insulin sensitizers and NAFLD with omentin levels must be answered by further study.
The most important limitation of our study is the lack of enough patients and healthy control group. The comparison of omentin levels of diabetic patients with NAFLD and healthy individuals can provide new information to the literature. Another limitation of our study is the randomly higher omentin levels of diet plus metformin group at the beginning of study.
In conclusion, although the effects of diet and diet plus metformin treatment on BMI of our results are consistent with the literature, but their effects on the omentin level is inconsistent. The important of omentin in the course of NAFLD remain unknown. Altogether, our study adds to the current evidence suggesting that omentin may have unusual role in the diabetics with NAFLD. Therefore, these observations have to be replicated in larger, better randomized trials with comparison of healthy individuals. 
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